amyloid/i̇nme

Bağlantı panoya kaydedilir

Sıralama türünü seçin

Sayfa 1 itibaren 26 Sonuçlar

Niacin compositions for reduction of amyloid beta peptide 42 (abeta 42) production and for treatment of Alzheimer's disease (AD)

Sadece kayıtlı kullanıcılar makaleleri çevirebilir

Giriş yapmak kayıt olmak

FIELD OF THE INVENTION The present invention relates to (1) phenolic ester hybrids of niacin with m-methoxy-p-hydroxy phenyl compounds like eugenol, vanillin, apocynin, ferulic acid, isoferulic acid and eugenol epoxide and (2) cocrystals of hybrids as above, particularly cocrystal of niacin-eugenol

5,6-dihydro-2H-[1,4]oxazin-3-yl-amine derivatives useful as inhibitors of beta-secretase (BACE)

Sadece kayıtlı kullanıcılar makaleleri çevirebilir

Giriş yapmak kayıt olmak

FIELD OF THE INVENTION The present invention relates to novel 5,6-dihydro-2H-[1,4]oxazin-3-ylamine derivatives as inhibitors of beta-secretase, also known as beta-site amyloid cleaving enzyme, BACE, BACE1, Asp2, or memapsin2. The invention is also directed to pharmaceutical compositions comprising

4,7-dihydro-pyrazolo[1,5-a]pyrazin-6-ylamine derivatives useful as inhibitors of beta-secretase (BACE)

Sadece kayıtlı kullanıcılar makaleleri çevirebilir

Giriş yapmak kayıt olmak

CROSS REFERENCE TO RELATED APPLICATIONS This application is the national stage of PCT Application No. PCT/EP2011/066343, filed Sep. 20, 2011, which claims priority from European Patent Application No. 10178315.7, filed Sep. 22, 2010 and European Patent Application No. 11157858.9, filed Mar. 11,

6,7-dihydro-pyrazolo[1,5-a]pyrazin-4-ylamine derivatives useful as inhibitors of beta-secretase (BACE)

Sadece kayıtlı kullanıcılar makaleleri çevirebilir

Giriş yapmak kayıt olmak

CROSS REFERENCE TO RELATED APPLICATIONS This application is the national stage of PCT Application No. PCT/EP2012/053455, filed Feb. 29, 2012, which claims priority from European Patent Application No. 11156463.9, filed Mar. 1, 2011, the entire disclosures of which are hereby incorporated in their

Benzoarylureido compounds, and composition for prevention or treatment of neurodegenerative brain disease containing the same

Sadece kayıtlı kullanıcılar makaleleri çevirebilir

Giriş yapmak kayıt olmak

CROSS REFERENCE TO RELATED APPLICATIONS This application is a national phase application, under 35 U.S.C. 371, of international application No. PCT/KR2009/007898, filed on Dec. 29, 2009, which claimed priority to Korean Patent Application No. 10-2008-0135519, filed on Dec. 29, 2008, the disclosures

Substituted 3,4-dihydropyrrolo[1,2-A]pyrazines as beta-secretase (BACE) inhibitors

Sadece kayıtlı kullanıcılar makaleleri çevirebilir

Giriş yapmak kayıt olmak

CROSS REFERENCE TO RELATED APPLICATIONS This application is the national stage of PCT Application No. PCT/EP2012/053863 filed Mar. 7, 2012, which claims priority from European Patent Application No. 11157418.2, filed Mar. 9, 2011, the entire disclosures of which are hereby incorporated in their

5,6-dihydro-imidazo[1,2-a]pyrazin-8-ylamine derivatives useful as inhibitors of beta-secretase (BACE)

Sadece kayıtlı kullanıcılar makaleleri çevirebilir

Giriş yapmak kayıt olmak

FIELD OF THE INVENTION The present invention relates to novel 5,6-dihydro-imidazo[1,2-a]pyrazin-8-ylamine derivatives as inhibitors of beta-secretase, also known as beta-site amyloid cleaving enzyme, BACE, BACE1, Asp2, or memapsin2. The invention is also directed to pharmaceutical compositions

4-Amino-6-phenyl-5,6-dihydroimidazo[1,5-a]pyrazin-3(2H)-one derivatives as inhibitors of beta-secretase (BACE)

Sadece kayıtlı kullanıcılar makaleleri çevirebilir

Giriş yapmak kayıt olmak

CROSS REFERENCE TO RELATED APPLICARIONS This application is the national stage of PCT Application No. PCT/EP2014/062283, filed Jun. 12, 2014, which claims priority from European Patent Application No. 13171723.3,filed Jun. 12, 2013, the entire disclosures of which are hereby incorporated in their

4-amino-6-phenyl-5,6-dihydroimidazo[1,5-A]pyrazine derivatives as inhibitors of beta-secretase (BACE)

Sadece kayıtlı kullanıcılar makaleleri çevirebilir

Giriş yapmak kayıt olmak

CROSS REFERENCE TO RELATED APPLICATIONS This application is the national stage of PCT Application No. PCT/EP2014/062285, filed Jun. 12, 2014, which claims priority from European Patent Application No. 13171730.8, filed Jun. 12, 2013, the entire disclosures of which are hereby incorporated in their

4-amino-6-phenyl-6,7-dihydro[1,2,3]triazolo[1,5-A]pyrazine derivatives as inhibitors of beta-secretase (BACE)

Sadece kayıtlı kullanıcılar makaleleri çevirebilir

Giriş yapmak kayıt olmak

CROSS REFERENCE TO RELATED APPLICATIONS This application is the national stage of PCT Application No. PCT/EP2014/062286, filed Jun. 12, 2014, which claims priority from European Patent Application No. 13171720.9, filed Jun. 12, 2013, the entire disclosures of which are hereby incorporated in their

Compound inhibiting activation of the enzyme Erk 1/2 to be used in the treatment of neurodegenerative illnesses

Sadece kayıtlı kullanıcılar makaleleri çevirebilir

Giriş yapmak kayıt olmak

FIELD OF THE INVENTION The present invention belongs to the field of medical chemistry and relates to the compound of formula (I), a primary triclyclic amine, which inhibits the tPA-induced activation of the enzyme Erk 1/2 and is promising for, the treatment of neurodegenerative illnesses, such as,

Tricyclic sulfonamides and their derivatives as inhibitors of matrix metalloproteinases

Sadece kayıtlı kullanıcılar makaleleri çevirebilir

Giriş yapmak kayıt olmak

BACKGROUND OF THE INVENTION The present invention relates to novel tricyclic sulfonamide compounds and their derivatives useful as pharmaceutical agents, to methods for their production, to pharmaceutical compositions which include these compounds and a pharmaceutically acceptable carrier, and to

Tricyclic sulfonamides and their derivatives as inhibitors of matrix metalloproteinases

Sadece kayıtlı kullanıcılar makaleleri çevirebilir

Giriş yapmak kayıt olmak

2,3,4,5-tetrahydropyridin-6-amine and 3,4-dihydro-2H-pyrrol-5-amine compound inhibitors of beta-secretase

Sadece kayıtlı kullanıcılar makaleleri çevirebilir

Giriş yapmak kayıt olmak

CROSS REFERENCE TO RELATED APPLICATIONS This application is the national stage of PCT Application No. PCT/EP2015/079981, filed Dec. 16, 2015, which claims priority from European Patent Application No. 14198977.2, filed Dec. 18, 2014 and European Patent Application No. 15164704.7, filed Apr. 22,

Biphenyl hydroxy imino butyric acids and their derivatives for treating arthritis

Sadece kayıtlı kullanıcılar makaleleri çevirebilir

Giriş yapmak kayıt olmak

BACKGROUND OF THE INVENTION The present invention relates to novel biphenyl butyric acid compounds and their derivatives useful as pharmaceutical agents, to methods for their production, to pharmaceutical compositions which include these compounds and a pharmaceutically acceptable carrier, and to

Facebook sayfamıza katılın

Herbal & Natural Medicine

Bilim tarafından desteklenen en eksiksiz şifalı otlar veritabanı

55 dilde çalışır
Bilim destekli bitkisel kürler
Görüntüye göre bitki tanıma
Etkileşimli GPS haritası - bölgedeki bitkileri etiketleyin (yakında)
Aramanızla ilgili bilimsel yayınları okuyun
Şifalı bitkileri etkilerine göre arayın
İlgi alanlarınızı düzenleyin ve haber araştırmaları, klinik denemeler ve patentlerle güncel kalın

Bir belirti veya hastalık yazın ve yardımcı olabilecek bitkiler hakkında bilgi edinin, bir bitki yazın ve karşı kullanıldığı hastalıkları ve semptomları görün.
* Tüm bilgiler yayınlanmış bilimsel araştırmalara dayanmaktadır